• Tue news: Pfizer explores sale of hospital drugs unit. FDA declines full approval of Ocaliva. AZ better than expected Q3 results. Pfizer, Lilly telehealth platforms draw scrutiny. 23andMe cutting lays off 40%. See more on our front page

Roche’s Genentech returns Alzheimer’s assets to AC Immune, cutting 18-year tie to the biotech

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Jan 22, 2024 at 11:42: AM
via Genentech is walking away from an 18-year relationship with AC Immune, handing back global rights to a pair of Alzheimer’s disease drug candidates after suffering a series of setbacks in the clinic.

article source
 




Top Bottom
Back
Quote